Moderna, Inc.
Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 clinical results
Company newsroom
Moderna, Inc.
NASDAQ:MRNA
1 releases